Trial of Tykerb for HER2-Positive Breast Cancer Brain Mets Begins

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 1
Volume 15
Issue 1

SAN ANTONIO—GlaxoSmithKline has announced the initiation of a global multicenter phase II trial (known as EGF 105084) to evaluate Tykerb (lapatinib) for the treatment of ErbB2 (HER2)-overexpressing breast cancer that has metastasized to the brain. Tykerb is an orally bioavailable small molecule that potently inhibits two receptors, ErbB2 and ErbB1. It is currently in development as a first-line treatment for ErbB2-overexpressing breast cancer.

SAN ANTONIO—GlaxoSmithKline has announced the initiation of a global multicenter phase II trial (known as EGF 105084) to evaluate Tykerb (lapatinib) for the treatment of ErbB2 (HER2)-overexpressing breast cancer that has metastasized to the brain. Tykerb is an orally bioavailable small molecule that potently inhibits two receptors, ErbB2 and ErbB1. It is currently in development as a first-line treatment for ErbB2-overexpressing breast cancer.

Articles in this issue
FDA Approves Nexavar for Use in Advanced Kidney Cancer
Avastin Benefits Metastatic Breast Cancer
Amgen to Acquire Abgenix
Better Prognosis for ‘Elsewhere' Local Breast Ca Recurrences
Herceptin/Taxotere Ups DFS in Early HER2+ Breast Ca
NIH 2006 Budget Is Likely to Be Lower Than in 2005
Amooranin, a Plant Compound, Shows Potential as Cancer Treatment
Mesenchymal Stem Cell Transplantation Potential Novel Treatment for Patients With Severe Graft-vs-Host-Disease
FDA Launches 7 Initiatives With European Drug Regulators
Taxanes Comparable as Adjuvant Therapy of Breast Cancer; Weekly Paclitaxel More Effective Than q3wk
Lessons From Ongoing Clinical Experience With MammoSite Breast Brachytherapy
Antibody Detects AML-Associated Stem Cells
Trial of Tykerb for HER2-Positive Breast Cancer Brain Mets Begins
Len/Dex for Relapsed or Refractory Myeloma
Encouraging Results With Ixabepilone in Metastatic Breast Ca
Recent Videos
3 experts in this video
3 experts in this video
3 experts in this video
Related Content
Expert Insights into the T-DXd Approval for HER2-Low or Ultralow Breast Cancer

Expert Insights into the T-DXd Approval for HER2-Low or Ultralow Breast Cancer

Ariana Pelosci
February 14th 2025
Article

Aditya Bardia, MD, discusses the FDA approval of T-DXd for HER2-low or ultralow metastatic breast cancer and its potential impact on treatment paradigms.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Pertuzumab retreatment modestly improved progression-free survival and meaningfully improved overall survival in advanced nHER2–positive breast cancer.

Retreatment With Pertuzumab/T-DM1 Improves PFS in HER2+ Breast Cancer

Roman Fabbricatore
February 12th 2025
Article

Pertuzumab retreatment modestly improved progression-free survival and meaningfully improved overall survival in advanced nHER2–positive breast cancer.

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Reducing Post-Mastectomy Disparities in Breast Cancer Minority Populations

Rachel A. Greenup, MD, MPH
December 23rd 2024
Podcast

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Managing Brain Metastases in Patients with HER2+ Metastatic Breast Cancer

Managing Brain Metastases in Patients with HER2+ Metastatic Breast Cancer

ONCOLOGY Staff
February 9th 2025
Article

The panel discussed the different ways to treat patients with HER2-positive metastatic breast cancer who also have brain metastases.

Risk model data may provide reassurance for individuals undergoing hormone therapy with an already heightened breast cancer risk due to family history.

Hormone Therapy Confers Modest Breast Cancer Risk Even With Family History

Russ Conroy
February 8th 2025
Article

Risk model data may provide reassurance for individuals undergoing hormone therapy with an already heightened breast cancer risk due to family history.